Julienne E. Bower

Julienne E. Bower

Auto-generated profile, based on publicly available information

Julienne E. Bower

Department of Psychology, University of California, Los Angeles

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2014 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JBJulienne E. Bower
Julienne E. Bower

3 February 2006 in Cancer
Verified
Journal Article
Open access
PDF file
JBJulienne E. Bower
Julienne E. Bower
PGPatricia A. Ganz
Patricia A. Ganz
KDKatherine A. Desmond
Katherine A. Desmond
CBCoen Bernaards
Coen Bernaards
JRJulia H. Rowland
Julia H. Rowland
TBThomas R. Belin
Thomas R. Belin
BACKGROUND: A longitudinal study was designed to evaluate the prevalence, persistence, and predictors of posttreatment fatigue in breast carcinoma survivors.METHODS: A sample of 763 breast carcinoma survivors completed questionnaires at 1–5 and 5–10 years after diagnosis, including the RAND 36‐item Health Survey, Center for Epidemiological Studies – Depression scale (CES‐D), Breast Cancer Prevention Trial Symptom Checklist, and demographic and treatment‐related measures.RESULTS: Approximately 34% of study participants reported significant fatigue at 5–10 years after diagnosis, which is consistent with prevalence estimates obtained at 1–5 years after diagnosis. Approximately 21% reported fatigue at both assessment points, indicating a more persistent symptom profile. Longitudinal predictors of fatigue included depression, cardiovascular problems, and type of treatment received. Women treated with either radiation or chemotherapy alone showed a small improvement in fatigue compared with those treated with both radiation and chemotherapy.CONCLUSIONS: Fatigue continues to be a problem for breast carcinoma survivors many years after cancer diagnosis, with 21% reporting persistent problems with fatigue. Several factors that may contribute to long‐term fatigue are amenable to intervention, including depression and comorbid medical conditions. Cancer 2006. © 2006 American Cancer Society.

1 July 2002 in Psychosomatic Medicine
Verified
Journal Article
Closed access
JBJulienne E. Bower
Julienne E. Bower
PGPatricia A. Ganz
Patricia A. Ganz
NANajib Aziz
Najib Aziz
JFJohn L. Fahey
John L. Fahey
Fatigue is a common problem among cancer patients and survivors, yet the mechanisms underlying the occurrence and persistence of this symptom are not known. Activation of the immune system may evoke feelings of fatigue, which are mediated by proinflammatory cytokines. We examined whether fatigued breast cancer survivors would show elevations in proinflammatory cytokines and markers of cytokine activity compared with nonfatigued survivors. Differences in lymphocyte subsets, cortisol, and behavioral symptoms associated with proinflammatory cytokines were also assessed. Forty breast cancer survivors (20 fatigued, 20 nonfatigued) provided blood samples at visits scheduled to control for diurnal variability. Cytokines, soluble markers of cytokine activity, and cortisol were measured by immunoassay and lymphocyte subsets by flow cytometry. Participants also completed questionnaires measuring demographic, medical, and behavioral variables. Fatigued breast cancer survivors had significantly higher serum levels of several markers associated with proinflammatory cytokine activity than nonfatigued survivors, including interleukin-1 receptor antagonist (IL-1ra), soluble tumor necrosis factor receptor type II (sTNF-RII), and neopterin. They were also more likely to report behavioral problems that co-occur with fatigue in the context of immune activation. Fatigued survivors had significantly lower serum levels of cortisol than the nonfatigued group as well as differences in two lymphocyte populations. Fatigued breast cancer survivors showed elevations in serum markers associated with proinflammatory cytokine activity an average of 5 years after diagnosis. Results suggest mechanisms through which enduring immune activation may occur, including alterations in cortisol and in lymphocyte subsets.

10 September 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JBJulienne E. Bower
Julienne E. Bower
PGPatricia A. Ganz
Patricia A. Ganz
MIMichael Irwin
Michael Irwin
LKLorna Kwan
Lorna Kwan
EBElizabeth C. Breen
Elizabeth C. Breen
SCSteve W. Cole
Steve W. Cole
Purpose: Fatigue, depression, and sleep disturbance are common adverse effects of cancer treatment and frequently co-occur. However, the possibility that inflammatory processes may underlie this constellation of symptoms has not been examined. Patients and Methods: Women (N = 103) who had recently finished primary treatment (ie, surgery, radiation, chemotherapy) for early-stage breast cancer completed self-report scales and provided blood samples for determination of plasma levels of inflammatory markers: soluble tumor necrosis factor (TNF) receptor II (sTNF-RII), interleukin-1 receptor antagonist, and C-reactive protein. Results: Symptoms were elevated at the end of treatment; greater than 60% of participants reported clinically significant problems with fatigue and sleep, and 25% reported elevated depressive symptoms. Women treated with chemotherapy endorsed higher levels of all symptoms and also had higher plasma levels of sTNF-RII than women who did not receive chemotherapy (all P < .05). Fatigue was positively associated with sTNF-RII, particularly in the chemotherapy-treated group (P < .05). Depressive symptoms and sleep problems were correlated with fatigue but not with inflammatory markers. Conclusion: This study confirms high rates of behavioral symptoms in breast cancer survivors, particularly those treated with chemotherapy, and indicates a role for TNF-α signaling as a contributor to postchemotherapy fatigue. Results also suggest that fatigue, sleep disturbance, and depression may stem from distinct biologic processes in post-treatment survivors, with inflammatory signaling contributing relatively specifically to fatigue.

10 February 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JBJulienne E. Bower
Julienne E. Bower
Behavioral symptoms are a common adverse effect of breast cancer diagnosis and treatment and include disturbances in energy, sleep, mood, and cognition. These symptoms cause serious disruption in patients' quality of life and may persist for years after treatment. Patients need accurate information about the occurrence of these adverse effects as well as assistance with symptom management. This review considers four of the most common behavioral sequelae of breast cancer, namely fatigue, sleep disturbance, depression, and cognitive impairment. Research on the prevalence, mechanisms, and treatment of each symptom is described, concluding with recommendations for future studies.

23 December 2014 in Cancer
Verified
Journal Article
Open access
PDF file
JBJulienne E. Bower
Julienne E. Bower
ACAlexandra D. Crosswell
Alexandra D. Crosswell
ASAnnette L. Stanton
Annette L. Stanton
CCCatherine M. Crespi
Catherine M. Crespi
DWDiana Winston
Diana Winston
PGPatricia A. Ganz
Patricia A. Ganz
BACKGROUND: Premenopausal women diagnosed with breast cancer are at risk for psychological and behavioral disturbances after cancer treatment. Targeted interventions are needed to address the needs of this vulnerable group.METHODS: This randomized trial provided the first evaluation of a brief, mindfulness‐based intervention for younger breast cancer survivors designed to reduce stress, depression, and inflammatory activity. Women diagnosed with early stage breast cancer at or before age 50 who had completed cancer treatment were randomly assigned to a 6‐week Mindful Awareness Practices (MAPS) intervention group (n = 39) or to a wait‐list control group (n = 32). Participants completed questionnaires before and after the intervention to assess stress and depressive symptoms (primary outcomes) as well as physical symptoms, cancer‐related distress, and positive outcomes. Blood samples were collected to examine genomic and circulating markers of inflammation. Participants also completed questionnaires at a 3‐month follow‐up assessment.RESULTS: In linear mixed models, the MAPS intervention led to significant reductions in perceived stress (P = .004) and marginal reductions in depressive symptoms (P = .094), as well as significant reductions in proinflammatory gene expression (P = .009) and inflammatory signaling (P = .001) at postintervention. Improvements in secondary outcomes included reduced fatigue, sleep disturbance, and vasomotor symptoms and increased peace and meaning and positive affect (P < .05 for all). Intervention effects on psychological and behavioral measures were not maintained at the 3‐month follow‐up assessment, although reductions in cancer‐related distress were observed at that assessment.CONCLUSIONS: A brief, mindfulness‐based intervention demonstrated preliminary short‐term efficacy in reducing stress, behavioral symptoms, and proinflammatory signaling in younger breast cancer survivors. Cancer 2015;121:1231–1240. © 2014 American Cancer Society.